Agoracom: Small Cap Investment - Zenith Epigenetics

...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Reply New Message

Back To Forum List View

KayakerBC

Dec 14, 2022 02:52PM

Re: 6%

fuzzyjr

Dec 14, 2022 03:46PM

Re: 6%

KayakerBC

Dec 15, 2022 10:11AM

Re: 6%

fuzzyjr

Dec 15, 2022 10:27AM

Re: 6%

KayakerBC

Dec 15, 2022 10:39AM

KOO-KOO2

Rank: Treasurer [?]

Points: 10765 [?]

Votes: 39 Score: 2.3 [?]

Your Vote:

Please Log In to Vote

Did you know? You can earn activity points by filling your profile with information about yourself (what city you live in, your favorite team, blogs etc.)

Re: 6%

in response to

Re: 6%

KayakerBC

posted on Dec 15, 2022 10:55AM

KBC, that would be the 6% Royalty steam paid to ZCC generated from the revenue that would come from successful ZEN-3694 in collaboration with BPs drugs. (vis-a-vis trials that are presently ongoing)

Koo

2 Recommendations

Re: 6%

fuzzyjr

Dec 15, 2022 11:10AM

Re: 6%

KOO-KOO2

Dec 15, 2022 11:21AM

Re: 6%

fuzzyjr

Dec 15, 2022 11:28AM

Re: 6%